drugset

drugset / Trial / NCT01622777

The Effect of Rosuvastatin in Diabetic Polyneuropathy: A Phase IIa Randomized Double-blind Placebo-controlled Study

NCT01622777 ↗

Phase 2 Completed 34 enrolled Alejandra Guillermina Miranda Diaz

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the impact of oral rosuvastatin in diabetic polyneuropathy, and the role of lipid peroxidation and nerve growth factor.

Timeline

Start: 2010-02
Primary completion: 2011-01
Completion: 2011-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rosuvastatin	Small molecule	20 mg	Oral

Indications